Revenue Growth Masks a Profit Collapse That Management Won't Explain
Q2 PAT crashed 78.7% sequentially despite revenue growing 26.8%. Management reiterated its refusal to provide earnings guidance, leaving the market to square an organic growth story with a profitability deterioration that remains undisclosed.
₹20.6 Cr
+44% YoY
−78.7%
revenue +26.8% QoQ
Gates accounting gain
Q1 PAT ~₹96.7 Cr implied
On the surface, Hester Biosciences' Q2 FY-2027 result reads like a strong quarter: revenue ₹97.9 Cr (+38% YoY), PAT ₹20.6 Cr (+44% YoY), with both India segments—Poultry Healthcare and Animal Health—posting double-digit growth. The market's bullish trend and the stock's position well above its 50-week moving averages reflect that reading. But beneath the headline numbers sits a jarring anomaly that management neither disclosed nor addressed on the call: PAT fell 78.7% quarter-over-quarter while revenue grew 26.8%. That gap is not a rounding error or a working capital swing. It signals either a sharp cost spike, a depreciation headwind, or an accounting shift—and management's silence on the cause is the real story of the quarter.
Where the profit really came from
The quarterly collapse becomes clearer when you decompose the H1 trend. Q2 PAT of ₹20.6 Cr represents a 78.7% QoQ decline, implying Q1 FY27 PAT was approximately ₹96.7 Cr—an exceptionally strong quarter. H1 FY27 total PAT was thus roughly ₹117.3 Cr. The earnings quality flag in the call analysis flags this explicitly: Q1 profit was inflated by a non-cash accounting gain when the Gates Foundation amended its loan to Hester Africa's subsidiary. When you strip out that exceptional item, Q1's organic profit was materially weaker than reported, and Q2's 78.7% QoQ drop marks a return to a normalized—but compressed—profit level. The organic picture is less 'strong momentum' and more a quarter where revenue grew faster than profit could keep pace.
Management's claims vs. what holds up
Revenue +38% YoY, PAT +44% YoY
SupportedExact: ₹97.9 Cr, +38%; ₹20.6 Cr, +44%
Strong momentum from Q1 to Q2; 'very strong base' set for H2
ContradictedPAT fell 78.7% QoQ despite revenue +26.8% QoQ
Poultry Healthcare +27% Q2, +37% H1
SupportedSegment growth rates consistent with ₹70+ Cr implied revenue range
Margin sustained at 78% gross, 35% EBITDA
MixedOPM 33.8%, NPM 20.8%; EBITDA/gross claims not independently validated from P&L
Extremely bullish on Africa; entered multiple export markets
OverstatedNo revenue, customer count, or order book disclosed. $1M loan injected but pre-scale
No foreign subsidiary losses; consolidated profit up 40%
OverstatedStated 44% YoY growth, not 40%; minor misquote
What changed on this call
Four material shifts from the Q1 call:
Export ratio upgraded: FY26 was 10%; FY27 expected higher but no specific pct. Management acknowledged 'definitely improved' trajectory.
Africa investment accelerated: Q1 call framed Africa as sustainability challenge. Q2: injected $1M loan, tone shifted to 'extremely bullish', market entry across Africa/Middle East/Asia flagged as near-term rollout.
Regulatory capex flagged: Management acknowledged 'increasingly rigorous' animal health documentation and trial requirements. May drive future capex; still in planning phase, no amount or timeline given.
Margin guidance hedged: Q1 implied confidence in 35% EBITDA sustainability. Q2 results deliver 35% EBITDA claimed but only 20.8% NPM, suggesting operating leverage isn't flowing through to net profit.
The bull-bear ledger
Poultry Healthcare is a genuine growth engine: +27% Q2, +37% H1, driven by institutional penetration and H9N2 vaccine contribution (though magnitude undisclosed).
Biologicals pipeline offers multi-year upside: Brucella recombinant, LPAI vaccine in regulatory pathway. BSL-3 lab and fill/finish facility are manufacturing assets with real scarcity value.
Africa operations backed by Gates Foundation credibility. Ruminant vaccine manufacturing unique to Africa is genuine differentiation vs competitors.
Capacity utilization at ~65% provides headroom to grow revenue without major capex in near term.
Gross margin stable at 78% across Q1, Q2, H1 suggests pricing power and cost discipline.
QoQ PAT collapse of 78.7% is unaddressed and unexplained. Red flag for either cost structure deterioration, depreciation headwind, or working capital swing that management is unwilling or unable to disclose.
H1 profit inflated by exceptional accounting gain, masking weaker organic trend. Adjusted H1 PAT ~₹85–90 Cr on ~₹180 Cr revenue is respectable but not exceptional.
Animal Health segment remains volatile: H1 FY27 −14% YoY despite Q2 +34%, signaling government tender seasonality or lumpy order flow. Execution risk.
Africa expansion claims unquantified. $1M loan injection is small relative to 'extremely bullish' narrative. Commercial traction and margin contribution unknown.
H9N2 vaccine sales contribution not disclosed, citing competitive sensitivity. Creates single-product concentration risk if repeat orders prove lumpy.
Management refused FY27 guidance for second consecutive quarter, maintaining opacity on near-term targets. Prior guidance track record is zero.
FII ownership declining (0.52% → 0.31% YTD). DII minimal (0.00%). Suggests institutional appetite cooling despite bullish price trend.
Risks, ranked by how much they should concern a holder
Profitability volatility masked by accounting gains
HighQ1 profit inflated by Gates accounting gain; Q2's organic level materially lower. If management continues to mix one-time items with operating profit, earnings quality becomes unreliable and valuation unsustainable.
QoQ profit collapse unaddressed
HighPAT fell 78.7% QoQ despite revenue +26.8%. A cost spike, depreciation headwind, or working capital swing of that magnitude should have been disclosed. Management's silence suggests operational surprise or deliberate opacity.
Animal Health segment seasonality
MediumH1 down 14% YoY but Q2 +34%, indicating government tender lumpy-ness. If Animal Health reverts to depressed run-rate in H2, it could mask underlying momentum and signal execution risk.
Africa execution and scale-up timelines
Medium$1M loan modest for 'extremely bullish' expansion narrative. No customer wins, order book, or margin roadmap disclosed. If Africa remains pre-commercial through FY27, return on Gates-backed investment will take years.
Regulatory capex uncertainty
MediumManagement flagged 'increasingly rigorous' animal health requirements but offered no specifics. If capex proves costlier than anticipated, near-term margins could compress further and capex cycle could strain balance sheet.
H9N2 vaccine product concentration
MediumPoultry Healthcare growth partly H9N2-driven but sales contribution not disclosed. H9N2 adoption is epidemic-driven; repeat orders may prove lumpy. If H9N2 demand cycles, Poultry momentum could stall abruptly.
FII/DII outflows amid bullish price action
Low-MediumFII ownership declined 0.21pp YTD to 0.31%; DII minimal. Stock up 91% off low, 30% off ATH. If institutional investors see profit deterioration as unsupported, further outflows could test momentum.
How the street is positioned
The stock closed at ₹2,372.9, bid in a bullish trend: above SMA20 (₹2,212), SMA50 (₹2,218), and SMA200 (₹1,937). It is up 91.47% from its 52-week low of ₹1,239.3 and sits ₹1,006.1 below its all-time high of ₹3,379 (−29.78% drawdown). RSI at 60.6 is neutral to warm, and volume is increasing—showing retail and tactical interest. However, institutional flows are mixed at best. FII ownership has declined from 0.52% a year ago to 0.31% as of Q1 FY27, and DII is minimal at 0.00%. That divergence—a bullish price trend coupled with FII retrenchment and a 91% recovery from lows—typically signals tactical retail accumulation in a stock with fundamental questions unresolved. The Q2 result, with its unexplained QoQ profit collapse and Africa expansion narrative short on numbers, is precisely the kind of earnings print that can stall momentum if the market begins to price in opacity and execution risk. Whether the stock sustains above SMA50 or tests SMA20 hinges on whether management addresses the QoQ deterioration in Q3 guidance.
The debate
What to watch next
1 · Q3 organic profit trajectory
Does PAT stabilize around ₹20–22 Cr per quarter (normalized ex-Q1 accounting gain), or does it continue to deteriorate? If Q3 PAT > ₹25 Cr, the QoQ collapse was one-time. If Q3 PAT < ₹18 Cr, margin compression is structural.
2 · Africa commercial traction disclosure
By Q3 or earlier: does management disclose first customer wins, order book size, expected H2/Q4 revenue contribution, or margin roadmap for Africa? $1M loan should catalyze visible momentum. Silence suggests pre-commercial delay.
3 · Animal Health H2 rebound execution
Animal Health was −14% YoY in H1 despite Q2 +34%, signaling tender seasonality. Does H2 post +25%+ growth to show Q1 lull was cyclical? If H2 is flattish, it suggests lumpy order flow and execution risk.
4 · Regulatory capex and guidance
By Q3: does management quantify animal health regulatory compliance capex? A specific number restores credibility. Continued vagueness signals either unpreparedness or competitive opacity, both red flags.
The number to track from here
Q3 organic PAT: Strip out accounting gains and focus on whether operational profit stabilizes around ₹20–25 Cr per quarter. If Q3 delivers that, the bullish momentum is justified and Africa optionality is genuine bonus. If Q3 PAT dips below ₹18 Cr, margin compression is structural and the stock is vulnerable to re-rating lower.
Hester Biosciences is not a broken company. Poultry Healthcare is a real growth asset, biologicals pipeline is credible, and Africa backed by Gates Foundation offers genuine optionality. But this quarter's profit deterioration coupled with management's refusal to explain it and to provide FY27 guidance puts the stock in a 'show me' stance. The 91% recovery from lows is impressive, but FII outflows into strength and a 30% drawdown from ATH are yellow lights. Hold the position, but demand answers in Q3. The bull case—managed Africa scale-up, biologicals approvals, Poultry Healthcare momentum—is intact. But the credibility case is at risk, and that matters more than sentiment when valuations have recovered this far.
Strong YoY growth masks QoQ PAT collapse; Africa expansion bullish but unquantified
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Maintained Q1 guidance pattern (no numeric targets); YoY metrics hit but QoQ deterioration not addressed on call.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 delivered solid YoY growth (revenue +38%, PAT +44%) backed by Poultry Healthcare momentum and improved product mix, but sequential PAT collapse of 78.7% despite 26.8% revenue growth signals margin deterioration that management did not disclose or explain. Africa expansion and biologicals pipeline offer multi-year upside but remain unquantified; near-term execution risk around Animal Health segment recovery and regulatory hurdles.
₹97.9 Cr
Revenue · +38% YoY₹20.6 Cr
Reported PAT · +44% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Revenue grew 38% YoY in Q2, PAT up 44%
METDelivered: revenue +38% YoY, PAT +44% YoY. Claims exactly match reported results.
Poultry Healthcare grew 27% in Q2 and 37% in H1
METClaims made but segment breakdown not separately verified against consolidated ₹97.9 Cr (Q2). Appears consistent with ₹70+ Cr range implied.
Margin maintained at 78% gross profit, 35% EBITDA
MixedDelivered: OPM 33.8%, NPM 20.8%. EBITDA/gross claims not independently validated from P&L.
Momentum from Q1 to Q2 maintained, 'strong base' set for H2
MISSQoQ revenue +26.8% but PAT collapsed -78.7% QoQ despite revenue growth. Profitability momentum severely broken.
No foreign entity subsidiaries making losses, consolidated profit up 40%
OVERSTATEDStated profit growth 44% YoY, not 40%. Minor discrepancy in quoted figure.
Very bullish on Africa, entered multiple export markets across Africa/Middle East/Asia
OVERSTATEDNo revenue/order book disclosed for Africa. Injecting $1M loan but business still pre-scale. Bullish sentiment unsupported by numbers.
Earnings quality
What changed since the last call
Margin outlook hedged vs Q1
DowngradeQ1 call: implied confidence in 35% EBITDA sustainability. Q2 results: EBITDA margin claimed at 35% but NPM only 20.8% vs implied 22-24% in prior year. Operating leverage not flowing through.
Export ambition elevated
UpgradeQ1 call: 10% of India revenue from exports. Q2 call: 'ratio would have definitely improved' but no number given. FY27 export contribution expected higher than FY26's 10%.
Africa investment accelerated
NewQ1 call: losses in Africa, focus on sustainability. Q2 call: injecting $1M loan, 'extremely bullish', entering Africa/ME/Asia markets. Tone shifted from defensive to offensive.
Regulatory headwinds acknowledged
NewQ2 call: 'regulatory requirements...increasingly rigorous, particularly around documentation, compliance and trial requirements.' Not material in Q2 but flagged as future capex pressure.
The Q&A
Analysts pressed hard on H9N2 sales breakdown, Africa execution details, and R&D asset capitalization. Management held firm on refusing H9N2 specifics ('won't be in position to give detailed volume led'), deflected Africa margin impact, and clarified R&D assets are development expenses. Tone was professional but protective on competitive sensitivity.
Export growth trajectory — Ankit, Zen Nivesh Advisors
PartialFY26 India exports ~10%; FY27 ratio would have definitely improved given new export opportunities embarked upon. No specific percentage given.
Africa intercompany loan — Ankit, Zen Nivesh Advisors
PartialLoan is 100% owned subsidiary requirement for fortification. Yes, will translate to improved Africa performance and multi-market entry. Bullish but non-numeric.
Capacity utilization and capex — Ankit, Zen Nivesh Advisors
PartialApproximately 65% utilization. Regulatory requirements may drive some capex, still in planning phase, will relook infrastructure from technology/compliance angles. No concrete number.
R&D asset capitalization — Madhur Rathi, Counter Cyclical Investments
AnsweredThese are R&D and licensing expenses for product development, capitalized till commercialization. All part of balance sheet, not separate BSL-3 depreciation.
Foreign subsidiary losses — Madhur Rathi, Counter Cyclical Investments
AnsweredNo specific separate entity making losses. Consolidated profit up 40%.
Poultry Healthcare product mix — Saurab, Paul Asset
DodgedPoultry vaccines are strength. Focus on institutional business penetration and customer engagement. H9N2 contributed but won't give detailed H9N2 volume or revenue split.
Animal Health tender pipeline — Madhur Rathi, Counter Cyclical Investments
PartialVery simple answer: yes, we want to maintain momentum. Both segments work differently, seasonalities differ. Strong base set, want to maintain.
Africa profitability roadmap — Manish Jain, GormalOne LLC
PartialFocus on ruminant vaccines in Africa, primarily producing there. Cannot be manufactured in India. Bullish on Africa but will not segment out Africa separately.
Guidance
No FY27 revenue target disclosed
LowManagement refuses specific targets, consistent with Q1 call. Growth from biologicals, Africa, poultry healthcare but no number attached.
EBITDA margin 35%, focus on sustained operational improvements
Medium35% EBITDA margin claimed for both Q2 and H1. OPM 33.8% in Q2 suggests 35% EBITDA is realistic mid-point, but margin trajectory is uncertain.
Capex for regulatory compliance and technology refresh TBD
LowRegulatory requirements for animal health products becoming 'increasingly rigorous'; may require incremental capex. No amount or timeline specified.
Risks the call surfaced
Profitability volatility
HighPAT fell 78.7% QoQ (revenue +26.8%) signaling cost spikes, working capital swing, or depreciation headwind not disclosed. Margin sustainability in doubt.
Regulatory compliance
MediumManagement flagged 'increasingly rigorous' regulatory requirements around documentation, compliance, and trials. Could delay product approvals and increase development capex.
Segment seasonality
MediumAnimal Healthcare H1 FY27 revenue 14% below prior year due to weak Q1 tender execution. Government procurement timings cause revenue lumpy-ness.
Africa execution risk
HighAfrica expansion described as 'extremely bullish' but unfunded until Q2 $1M injection; market entry across continent but no revenue/customer traction disclosed.
Product concentration
MediumPoultry Healthcare +27% Q2 driven partly by H9N2 vaccine but management refused to quantify H9N2 revenue share or repeat customer base.
Management
Score 7/10. Clear on strategy (biologicals, Africa, institutional reach) but evasive on numbers (H9N2 sales, Africa revenue, exact capex). Candid on regulatory challenges; transparent on losses. Delivered Q2 YoY targets (+38% rev, +44% PAT) but Q1 profitability was exceptional (accounting gain), masking organic trend. QoQ collapse unaddressed. Track record mixed.
1 · Q3 FY27
Animal Health tender execution momentum and H9N2 vaccine commercial traction (refused detail)
2 · By Nov 15 2026
Completion of ₹1M intercompany loan to Hester Africa for working capital and market development
3 · H2 FY27
Biologicals pipeline regulatory approvals (Brucella recombinant, LPAI vaccine); Africa ruminant vaccine commercialization
Africa expansion and biologicals pipeline offer multi-year upside but remain unquantified; near-term execution risk around Animal Health segment recovery and regulatory hurdles.
Hester Biosciences Q2 FY27: consolidated PAT +44% YoY as EBITDA margin expands to 37%
PAT +44% YoY · revenue +38% · margins expanding
₹97.91 Cr
+38% YoY
₹20.63 Cr
+44% YoY
20.75%
+3pp YoY
₹23.94
Hester Biosciences' consolidated (primary) revenue came in at ₹97.91 Cr, up 38% YoY and 27% QoQ, with PAT of ₹20.63 Cr, up 44% YoY as reported (~41% on an adjusted basis stripping a minor ₹0.42 Cr exceptional gain this quarter — the year-ago quarter had no exceptional items, so the YoY comparison is largely clean). Standalone, the core India entity, posted revenue of ₹82.93 Cr (+28% YoY) and PAT of ₹16.66 Cr (+131% YoY). This is a micro-cap with no analyst consensus coverage located for this print, so street expectations are unknown rather than beaten or missed.
Q2 FY-2027 vs prior quarters
The growth was margin-led as much as volume-led: standalone gross margin rose to 78% from 68% a year ago and EBITDA margin to 35% from 21%, which management attributes to a favourable product mix and cost discipline; consolidated EBITDA margin expanded to 37% from 33%. Poultry Healthcare (standalone) grew revenue 27% YoY on institutional penetration and customer engagement, while Animal Healthcare grew 34% YoY in the quarter on tender execution — though H1 Animal Healthcare revenue is still down 14% YoY on a weak Q1 tender cycle, a seasonality/timing effect rather than demand loss. Management's own framing credits consolidated growth primarily to "the strong performance of the India business," with international operations "broadly stable."
The stock went into the print at ₹2,479.1, up 13.5% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
No formal forward guidance. Management maintains long-term confidence in biologicals portfolio, international expansion, and R&D pipeline (Brucella recombinant, LPAI vaccine commercialization) but refuses specific FY27 revenue/margin targets. Africa tax-free status till 2030.
Management gave no formal FY27 revenue or margin guidance at the last concall and none accompanies this result either; that stance is unchanged. The headline QoQ swing — consolidated PAT down 79% from ₹96.73 Cr in Q1 FY27 — is not a deterioration: Q1's figure was inflated by an ₹85.77 Cr non-recurring gain after Hester Africa's loan with the Gates Foundation was amended (principal cut from USD 12 Mn to USD 5 Mn, accrued interest waived, remaining balance made interest-free), booked as an Ind AS 109 extinguishment gain. Stripped of that, Q2's underlying consolidated performance is a sequential improvement, not a decline. Alongside results, the board approved a fresh unsecured USD 1 Mn loan to Hester Africa (9% interest, 3-year tenure) and the company completed divestment of its remaining 11% stake in Texas Lifescience Pvt Ltd, concluding the partial exit begun with last year's 43.81% stake sale.
W1
Whether consolidated EBITDA margin holds near 37% (vs 33% a year ago) once the one-off's residual effects fully roll off in Q3
W2
Animal Healthcare division: Q2 grew 34% YoY on tender execution but H1 is still -14% YoY — watch if Q3 tender flow sustains the recovery
W3
Utilisation of the new USD 1 Mn Hester Africa loan (agreement expected by 15 November 2026) against stated international expansion plans
Consolidated PBT (₹26.454 Cr) = totalIncome−totalExpenses (₹24.131 Cr) + JV profit share (₹1.904 Cr) + exceptional gain (₹0.419 Cr) — both sit below the 'total expenses' line by design. Year-ago quarter had no exceptional item, so YoY is clean; QoQ is distorted by Q1 FY27's ₹85.77 Cr one-time Gates Foundation loan-modification gain at Hester Africa.